Wednesday 17 January 2018 ShareProphets: The one stop source for breaking news, expert analysis, and podcasts on fast-moving AIM and LSE listed shares

Exclusive: Optibiotix - CEO O'Hara comments on SlimBiome

By Tom Winnifrith | Sunday 26 June 2016

Disclosure: Financial Investigative Media Limited, which is not owned by Tom Winnifrith but by a trust for his dependants, owns shares in companies mentioned in this article. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.

Certain folks have noticed that a product range called Slimbione has gone on sale and asked if it is anything to do with Optibiotix (OPTI). Here is what CEO Steve O'Hara told us exclusively:

We have a small scale pilot launch of snack bars and shakes containing our SlimBiome product. Industry often use these type of soft launches to iron out any wrinkles in products and test customer approval so that modifications can be made prior to a full launch (e.g. courier, website e commerce, packaging, flavours etc).

The products are sold on the website to a limited number of customers introduced by us who provide feedback. We have just started testing Amazon as an outlet. We have not advertised the product.

This has been carried out in full consultation with the regulator and we are both of the view that at this stage given its a pilot launch that currently it is not market sensitive

If the launch is successful we will confirm commercial agreements, proceed to full commercialisation, and make the necessary regulatory announcements.


That sounds rather on the promising side to me. We all know how massive this market could be. The shares slipped back to 79p-80p on Friday as part of the wider post referendum sell off. If you can buy at 80p or under you should as, on hard news, this one could race ahead, the story is getting ever more exciting.

Filed under:

Never miss a story.

This area of the site is for independent financial commentary. These blogs are provided by independent authors via a common carrier platform and do not represent the opinions of does not monitor, approve, endorse or exert editorial control over these articles and does not therefore accept responsibility for or make any warranties in connection with or recommend that you or any third party rely on such information. The information available at is for your general information and use and is not intended to address your particular requirements. In particular, the information does not constitute any form of advice or recommendation by and is not intended to be relied upon by users in making (or refraining from making) any investment decisions.

More on OPTI


Comments are turned off for this article.

Site by Everywhen